Comparison of autologous, matched sibling, and alternative donor stem cell transplant outcomes for acute myeloid leukemia patients in first remission: A propensity score matching study

Article Multidisciplinary Sciences

The epidemiology, treatment patterns, healthcare utilizations and costs of Acute Myeloid Leukaemia (AML) in Taiwan

Huai-Hsuan Huang et al.

Summary: This study is the first population-based study conducted in Asia to provide updated and comprehensive information on the epidemiology, treatment patterns, healthcare resource utilization, and costs of AML.

PLOS ONE (2022)

添加到收藏夹

Article Hematology

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN

Hartmut Doehner et al.

Summary: The 2010 and 2017 editions of the European LeukemiaNet recommendations for AML diagnosis and management are widely recognized. There have been major advances in our understanding of AML, including disease classification updates, improvements in genomic diagnostics, and the development of new therapeutic agents. This update includes a revised genetic risk classification, response criteria, and treatment recommendations.

BLOOD (2022)

添加到收藏夹

Article Medicine, General & Internal

Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes

Sijian Yu et al.

Summary: This study aimed to investigate PRT choices based on dynamic MRD in patients with IR-AML. The results suggest that clinical decisions based on dynamic MRD might be associated with improved therapy stratification and optimized PRT for patients with IR-AML.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Article Hematology

Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study

Eduardo Rodriguez-Arboli et al.

Summary: In AML patients with intermediate risk cytogenetics, autologous stem cell transplantation may be a valid option for those with favorable molecular risk, while matched sibling donor alloSCT should be the preferred postremission strategy for patients with intermediate molecular risk.

TRANSPLANTATION AND CELLULAR THERAPY (2021)

添加到收藏夹

Article Hematology